Their study demonstrated that these effects were reduced in p53-mutant cells and increased in wild-type p53 cells, suggesting an essential role of p53 in establishing the effects of these agents in pancreatic cancer cells. This evidence concerns the gene TP53 and pancreatic neoplasm.